Mike Minh Fernandez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mike Minh Fernandez has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Lili Wang
Department of Systems Biology, Beckman Research Institute, City of Hope, Duarte, USA
85 shared publications - Kevyn Lopez Hart
Department of Systems Biology, Beckman Research Institute, City of Hope National Comprehensive Cancer Center, Monrovia, California. 1
84 shared publications - Ren-Jang Lin
Irell & Manella Graduate School of Biological Sciences of the City of Hope, Duarte, CA, USA.
73 shared publications - Qiong Jia
Department of Botany & Plant Sciences, University of California, Riverside, CA 92527, USA
72 shared publications - Lei Yu
Quantitative Biomedical Research Center, Department of Health Data Science & Biostatistics, Peter O’Donnell Jr. School of Public Health, UT Southwestern Medical Center, Dallas, USA
71 shared publications - Xuesong Wang
Department of Animal Science, North Carolina State University, 120 W Broughton Drive, Raleigh, NC 27607, United States
71 shared publications
Latest Publications
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-8 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Fig S1. SF3B1 mutant CLL samples had pervasive changes in 3’ splice site. Fig S2. Omics analyses identify widespread post-transcriptional upregulation of splicing factors in CLL. Fig S3. Abundance of spliceosome complexes and RNA-binding proteins are associated with clinical outcomes in CLL. Fig S4. METTL3 is consistently upregulated along with differential m6A modification on transcripts of RNA splicing process in CLL. Fig S5. KO or pharmacological inhibition of METTL3 impacts cell growth. Fig S6. KO or pharmacological inhibition of METTL3 impacts apoptosis, cell cycle, and splicing factor abundance. Fig S7. Splicing factors are either direct or indirect targets of METTL3. Fig S8. Validation of association between m6A and splicing factor abundance using dCasRx-METTL3.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-8 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Fig S1. SF3B1 mutant CLL samples had pervasive changes in 3’ splice site. Fig S2. Omics analyses identify widespread post-transcriptional upregulation of splicing factors in CLL. Fig S3. Abundance of spliceosome complexes and RNA-binding proteins are associated with clinical outcomes in CLL. Fig S4. METTL3 is consistently upregulated along with differential m6A modification on transcripts of RNA splicing process in CLL. Fig S5. KO or pharmacological inhibition of METTL3 impacts cell growth. Fig S6. KO or pharmacological inhibition of METTL3 impacts apoptosis, cell cycle, and splicing factor abundance. Fig S7. Splicing factors are either direct or indirect targets of METTL3. Fig S8. Validation of association between m6A and splicing factor abundance using dCasRx-METTL3.
- Open Access
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-5 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Table S1 shows CLL sample information; Table S2 shows protein expression detected in CLL and normal B cells using TMT proteomics; Table S3 shows top 150 transcripts with highest m6A density in B cells; Table S4 shows sequences of shRNAs, sgRNAs, and primers used in our study; Table S5 shows cellular pathways enriched in our study.
- 24 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-5 from METTL3-Mediated m6A Modification Controls Splicing Factor Abundance and Contributes to Aggressive CLL
Table S1 shows CLL sample information; Table S2 shows protein expression detected in CLL and normal B cells using TMT proteomics; Table S3 shows top 150 transcripts with highest m6A density in B cells; Table S4 shows sequences of shRNAs, sgRNAs, and primers used in our study; Table S5 shows cellular pathways enriched in our study.
- Open Access
- 22 July 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (17)
SF3B1 mutation accelerates the development of CLL via activation of the mTOR pathway
RNA splicing factor SF3B1 is one of the most recurrently mutated genes in chronic lymphocytic leukemia (CLL) and frequently co-occurs with chromosome 13q deletion (del(13q)). This combination is associated with poor prognosis in CLL, suggesting these lesions increase CLL aggressiveness. While del(13q) in murine B cells (Mdr mice), but not expression of Sf3b1-K700E, drives the initiation of CLL, we hypothesize that SF3B1 mutation accelerates CLL progression. In this study, we crossed mice with a B-cell-specific Sf3b1-K700E allele with Mdr mice to determine the impact of Sf3b1 mutation on CLL progression. We found that the co-occurrence of these two lesions in murine B cells caused acceleration of CLL. We showed that Sf3b1-K700E impacted alternative RNA splicing of Nfatc1 and activated mTOR signaling and the MYC pathway, contributing to CLL acceleration. Moreover, concurrent inhibition of RNA splicing and mTOR pathways led to cell death in vitro and in vivo in murine CLL cells with SF3B1 mutation and del(13q). Our results thus suggest that SF3B1 mutation contributes to the aggressiveness of CLL by activating the mTOR pathway through alternative splicing of Nfatc1, providing a rationale for targeting mTOR and RNA splicing in the subset of CLL patients with both SF3B1 mutations and del(13q).
- 22 July 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (17)
Open AccessSF3B1 mutation accelerates the development of CLL via activation of the mTOR pathway
RNA splicing factor SF3B1 is one of the most recurrently mutated genes in chronic lymphocytic leukemia (CLL) and frequently co-occurs with chromosome 13q deletion (del(13q)). This combination is associated with poor prognosis in CLL, suggesting these lesions increase CLL aggressiveness. While del(13q) in murine B cells (Mdr mice), but not expression of Sf3b1-K700E, drives the initiation of CLL, we hypothesize that SF3B1 mutation accelerates CLL progression. In this study, we crossed mice with a B-cell-specific Sf3b1-K700E allele with Mdr mice to determine the impact of Sf3b1 mutation on CLL progression. We found that the co-occurrence of these two lesions in murine B cells caused acceleration of CLL. We showed that Sf3b1-K700E impacted alternative RNA splicing of Nfatc1 and activated mTOR signaling and the MYC pathway, contributing to CLL acceleration. Moreover, concurrent inhibition of RNA splicing and mTOR pathways led to cell death in vitro and in vivo in murine CLL cells with SF3B1 mutation and del(13q). Our results thus suggest that SF3B1 mutation contributes to the aggressiveness of CLL by activating the mTOR pathway through alternative splicing of Nfatc1, providing a rationale for targeting mTOR and RNA splicing in the subset of CLL patients with both SF3B1 mutations and del(13q).
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 10 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Supplementary Table 10 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 10 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Supplementary Table 10 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
FACS sorting and RhAMP SNP screening yield isogenic SF3B1 mutant clones
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
FACS sorting and RhAMP SNP screening yield isogenic SF3B1 mutant clones
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Supplementary Table 6 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Supplementary Table 6 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Supplementary Table 7 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Supplementary Table 7 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Cloning and mutagenesis primers
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Cloning and mutagenesis primers
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Splicing and growth phenotypes of HG-3 and MEC-1 SF3B1 mutant cell lines
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Splicing and growth phenotypes of HG-3 and MEC-1 SF3B1 mutant cell lines
- Open Access
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Supplementary Table 3 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
- 3 April 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis
Supplementary Table 3 from Engineering Oncogenic Hotspot Mutations on SF3B1 via CRISPR-Directed PRECIS Mutagenesis